Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques

scientific article published on 27 July 2016

Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/JVI.01163-16
P932PMC publication ID5021426
P698PubMed publication ID27466414

P50authorBernard MossQ822617
Rama Rao AmaraQ88444844
Bali PulendranQ88744806
Paul SpearmanQ92752230
Sudhir Pai KasturiQ96176484
Rafiq NabiQ117274385
David C. MontefioriQ63302725
Celia C LaBrancheQ63422835
Georgia D. TomarasQ63663866
Pamela A KozlowskiQ88438362
Sailaja GangadharaQ88444841
P2093author name stringXiaoying Shen
Pradeep B J Reddy
Xuemin Chen
Smita S Iyer
Blandine Victor
Michael J Sabula
P2860cites workImmune correlates of vaccine protection against HIV-1 acquisitionQ26778573
A brief history of the global effort to develop a preventive HIV vaccineQ26851165
Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal ChallengeQ27318151
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing EpitopesQ28271300
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimersQ28647225
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandQ29547531
Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine.Q30365998
Programming the magnitude and persistence of antibody responses with innate immunityQ30400144
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samplesQ30498394
Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trialQ30532861
A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profilingQ30648718
Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivoQ33328336
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesQ33813145
Why HIV virions have low numbers of envelope spikes: implications for vaccine developmentQ34016070
CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challengeQ34059531
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infectionQ34402934
Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protectionQ34444625
Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251.Q34462107
Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeysQ34594754
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccineQ34619904
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesQ34772727
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaQ34848486
Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.Q34982651
Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremiaQ35105449
Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus MacaquesQ35864543
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman PrimatesQ35914306
Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccineQ36141586
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccineQ36407775
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.Q36489415
Analysis of simian immunodeficiency virus sequence variation in tissues of rhesus macaques with simian AIDSQ36654291
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.Q36895518
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeysQ37355237
HIV-specific antibody-dependent phagocytosis matures during HIV infection.Q38873975
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.Q39874667
Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assaysQ39988991
Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination.Q51890555
Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.Q51968415
Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibodyQ73030181
P433issue19
P407language of work or nameEnglishQ1860
P921main subjectSimian immunodeficiency virusQ1890246
Vaccinia virusQ1986297
P304page(s)8842-8854
P577publication date2016-07-27
P1433published inJournal of VirologyQ1251128
P1476titleVirus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques
P478volume90

Reverse relations

cites work (P2860)
Q89790335A bivalent, spherical virus-like particle vaccine enhances breadth of immune responses against pathogenic Ebola viruses in rhesus macaques
Q47296227A trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques
Q56517308Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques
Q37628515Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine
Q33865785Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy
Q63246465HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge
Q92152909Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Ch
Q37633417Native-like Env trimers as a platform for HIV-1 vaccine design
Q57282350Oral co-administration of an intramuscular DNA/ Modified Vaccinia Ankara vaccine for simian immunodeficiency virus is associated with better control of infection in orally exposed infant macaques
Q91890041Rectal Microbiome Composition Correlates with Humoral Immunity to HIV-1 in Vaccinated Rhesus Macaques
Q40116011Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice
Q94562592T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers
Q38621582The Impact of Poxvirus Vector Priming, Protein Co-Administration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques
Q47276928Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins
Q90226623Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV
Q52655238Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.

Search more.